Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2023 | EHA 2023 T-cell lymphoma highlights

Swaminathan Iyer • 10 Jun 2023
EHA 2023
Lymphoma Rare Diseases T-Cell Lymphoma

Swaminathan Iyer, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, shares some of his highlights in T-cell lymphoma (TCL) from this year’s EHA meeting, commenting on a TRBC1-targeting CAR-T therapy for TCL, as well as preclinical studies highlighting the importance of targeting macrophages. This interview took place at the 28th Congress of the European Hematology Association (EHA) 2023 in Frankfurt, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

CRISPR, SEAGEN, MERCK, RHIZEN, ACROTECH, LEGEND, INNATE

More from Swaminathan Iyer

3:17
PET imaging to predict treatment outcomes: follow-up from the ECHELON-2 trial
Swaminathan Iyer • 11 Dec 2023
2:39
The significance of CD30 in the response to brentuximab vedotin for patients with T-cell lymphoma
Swaminathan Iyer • 11 Dec 2023
5:32
A machine learning model to analyze histopathological tissue in DLBCL
Swaminathan Iyer • 11 Dec 2023
2:57
Lacutamab, an anti-KIR3DL2 monoclonal antibody, in the treatment of R/R PTCL
Swaminathan Iyer • 11 Dec 2023

Related Videos

3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
2:11
The role of CAR-T therapy for lymphoma in 2024: expert session highlights
Sridhar Chaganti • 16 Apr 2024
3:18
Immune-mediated bone marrow failure diseases & their pathophysiology: aplastic anemia, LR-MDS & PNH
Carlo Dufour • 15 Apr 2024
1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals